Literature DB >> 11982727

Management of refractory ascites and hepatorenal syndrome.

Anuchit Chutaputti1.   

Abstract

Refractory ascites and hepatorenal syndrome (HRS) are the late complications of the terminal stages of cirrhosis. The definitions of refractory ascites and HRS proposed by the International Ascites Club in 1996 are now widely accepted, and are useful in diagnosis, treatment and research in this field. In both conditions, the only treatment of proven value for improved survival is liver transplantation. However, because of better understanding about the pathophysiology of HRS, including the roles of portal hypertension, ascites formation and hemodynamic derangements, treatments such as transjugular intrahepatic portasystemic shunt (TIPS) and new pharmacological agents may be considered to alleviate the problem prior to transplantation. Symptomatic treatment of refractory ascites includes TIPS and repeated large volume paracentesis. Transjugular intrahepatic portasystemic shunt can improve survival while waiting for liver transplantation. Practical management guidelines for TIPS and large volume paracentesis, including the prevention and management of further complications, are considered in this review. Copyright 2002 Blackwell Publishing Asia Pty Ltd

Entities:  

Mesh:

Year:  2002        PMID: 11982727     DOI: 10.1046/j.1440-1746.2002.02724.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  2 in total

1.  Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial.

Authors:  Yoshiyuki Narahara; Hidenori Kanazawa; Takeshi Fukuda; Yoko Matsushita; Hirotomo Harimoto; Hideko Kidokoro; Tamaki Katakura; Masanori Atsukawa; Yasuhiko Taki; Yuu Kimura; Katsuhisa Nakatsuka; Choitsu Sakamoto
Journal:  J Gastroenterol       Date:  2010-07-15       Impact factor: 7.527

2.  Predictors of refractory ascites development in patients with hepatitis B virus-related cirrhosis hospitalized to control ascitic decompensation.

Authors:  Ju Hee Seo; Seung Up Kim; Jun Yong Park; Do Young Kim; Kwang-Hyub Han; Chae Yoon Chon; Sang Hoon Ahn
Journal:  Yonsei Med J       Date:  2013-01-01       Impact factor: 2.759

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.